These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 41558)

  • 21. Stereoselectivity in the metabolism of the beta-adrenergic blocking agent, (+/-)-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride (xibenolol hydrochloride, D-32), in man.
    Honma S; Ito T; Kambegawa A
    Chem Pharm Bull (Tokyo); 1985 Feb; 33(2):760-8. PubMed ID: 2861914
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system.
    Cappello B; De Rosa G; Giannini L; La Rotonda MI; Mensitieri G; Miro A; Quaglia F; Russo R
    Int J Pharm; 2006 Aug; 319(1-2):63-70. PubMed ID: 16650700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist [proceedings].
    Boudot JP; Cavero I; Fénard S; Lefèvre-Borg F; Manoury P; Roach AG
    Br J Pharmacol; 1979 Jul; 66(3):445P. PubMed ID: 43176
    [No Abstract]   [Full Text] [Related]  

  • 24. Comment on the comment on nadolol article.
    Drug Intell Clin Pharm; 1981; 15(7-8):603. PubMed ID: 6113946
    [No Abstract]   [Full Text] [Related]  

  • 25. Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].
    Bianchetti G; Gomeni R; Kilborn JR; Morselli PL; Taylor EA; Warrington SJ
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P-404P. PubMed ID: 41556
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparative ex vivo drug permeation study of beta-blockers through porcine buccal mucosa.
    Amores S; Lauroba J; Calpena A; Colom H; Gimeno A; Domenech J
    Int J Pharm; 2014 Jul; 468(1-2):50-4. PubMed ID: 24727142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic studies on CS-359, a new beta-adrenergic blocking agent. I. Isolation and identification of the urinary metabolites of CS-359.
    Hayashi R; Okada M; Nakazawa T; Tanaka Y; Shimoji Y
    Chem Pharm Bull (Tokyo); 1975 Jun; 23(6):1173-83. PubMed ID: 241498
    [No Abstract]   [Full Text] [Related]  

  • 28. [The metabolism of the beta receptor blocker talinolol in humans--relationship between structure, polarity and amount excreted].
    Oertel R; Richter K
    Pharmazie; 1995 Sep; 50(9):637-8. PubMed ID: 7480105
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 30. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
    Yedurkar P; Dhiman MK; Petkar K; Sawant K
    J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocker SL 75212 in healthy volunteers [proceedings].
    Bianchetti G; Cadigan PJ; Gomeni R; Kilborn JR; London DR; Morselli PL; Pentecost BL
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P. PubMed ID: 41555
    [No Abstract]   [Full Text] [Related]  

  • 32. Absorption characteristics of insulin through the buccal mucosa.
    Oh CK; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1990 May; 12(4):275-9. PubMed ID: 2197519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphism in drug metabolism.
    Balant L; Dayer P; Fabre J
    Br Med J; 1978 Nov; 2(6147):1299. PubMed ID: 30518
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical pharmacology of trimepranol (pharmacokinetic informations and effects on heart rate in healthy individuals)].
    Mayer O; Petrlík M; Vitous J; Cepelák V
    Vnitr Lek; 1976 Nov; 22(11):1102-9. PubMed ID: 12612
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenetics and heart failure: a convergence with carvedilol.
    Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
    Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical pharmacokinetics and metabolism of bevantolol.
    Latts JR
    Angiology; 1986 Mar; 37(3 Pt 2):221-5. PubMed ID: 2871781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of changes in buccal potential difference on the buccal absorption of propranolol.
    Hitoglou-Makedou A; Hedges A; Turner P
    J Pharm Pharmacol; 1989 Oct; 41(10):712-3. PubMed ID: 2575151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ocular tissue distributions of befunolol hydrochloride, a beta-adrenergic blocking agent, after intravitreous or subconjunctival injection into the albino and pigmented rabbits].
    Ishii Y; Matsumura Y; Shirasawa E; Araie M
    Nippon Ganka Gakkai Zasshi; 1984 Oct; 88(10):1278-86. PubMed ID: 6151807
    [No Abstract]   [Full Text] [Related]  

  • 39. [Stereoselective glucuronidation of beta-blocking agents, 1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32) and propranolol, in animals, in vivo and in vitro].
    Honma S; Ito T; Matsuki Y
    Yakugaku Zasshi; 1986 May; 106(5):406-13. PubMed ID: 2876088
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies on metabolic reduction of befunolol in rabbit liver and kidney.
    Imamura Y; Nozaki Y; Imai T; Otagiri M
    Chem Pharm Bull (Tokyo); 1988 Feb; 36(2):708-12. PubMed ID: 2900698
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.